SUPN Q1 2023 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$154M+0.8% YoY

Gross Profit

$130M84.7% margin

Operating Income

$5M3.4% margin

Net Income

$17M11.0% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

-8.1%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$880M

Stockholders' Equity

$912M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$154M	$153M	+0.8%
Gross Profit	$130M	$135M	-3.2%
Operating Income	$5M	$2M	+163.1%
Net Income	$17M	$26M	-33.8%

Revenue Segments

Product

$141M48%

Trokendi Xr

$35M12%

Oxtellar X R

$29M10%

GOCOVRI

$26M9%

Qelbree

$26M9%

APOKYN

$17M6%

Royalty

$13M4%

Manufactured Product, Other

$8M3%